Clinical Trials Browser

Phase 2 × Neoplasms, Plasma Cell × 90 days × Clear all

NCT00544115 2026-06-02

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cellSarcoma

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Burkitt Lymphoma, Graft vs Host Disease, Hemoglobinuria, Paroxysmal, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Precancerous Conditions, Recurrence, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Dendritic Cell Sarcoma, Interdigitating, Primary Myelofibrosis

NCT04649359 2026-05-19

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Phase 2 Active not recruiting

187 enrolled 14 charts 1 FDA

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Phase 2 Active not recruiting

160 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT05336383 2026-04-15

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Phase 2 Recruiting

30 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03500445 2026-04-13

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Phase 2 Active not recruiting

75 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04680468 2026-03-23

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

Phase 2 Active not recruiting

41 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT02952508 2026-03-18

CLOVER-WaM

Phase 2 Active not recruiting

120 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell